Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion provides contract services include...
- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services
Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.
Latest funding size
Time since last funding
|over 9 years|
|Invest Northern Ireland, Viridian Investment Partners, Crescent Capital, QUBIS, University Challenge Fund|
|FY, 2014||FY, 2013|
|£723 K||£405 K|
Revenue growth, %
Cost of sales
|£365 K||£324 K|
|£358 K||£80.8 K|
Gross profit Margin, %
Operating expense total
|£477 K||£554 K|